Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture
- PMID: 20009036
- PMCID: PMC2837335
- DOI: 10.1182/blood-2009-09-244962
Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture
Abstract
Although the involvement of plasminogen activator inhibitor-1 (PAI-1) in fibrotic diseases is well documented, its role in cardiac fibrosis remains controversial. The goal of this study was to determine the effect of a PAI-1 deficiency (PAI-1(-/-)) on the spontaneous development of cardiac fibrosis. PAI-1(-/-) mice developed pervasive cardiac fibrosis spontaneously with aging, and these mice displayed progressively distorted cardiac architecture and markedly reduced cardiac function. To mechanistically elucidate the role of PAI-1 in cardiac fibrosis, 12-week-old mice were chosen to study the biologic events leading to fibrosis. Although fibrosis was not observed at this early age, PAI-1(-/-) hearts presented with enhanced inflammation, along with increased microvascular permeability and hemorrhage. A potent fibrogenic cytokine, transforming growth factor-beta (TGF-beta), was markedly enhanced in PAI-1(-/-) heart tissue. Furthermore, the expression levels of several relevant proteases associated with tissue remodeling were significantly enhanced in PAI-1(-/-) hearts. These results suggest that PAI-1 is cardioprotective, and functions in maintaining normal microvasculature integrity. Microvascular leakage in PAI-1(-/-) hearts may provoke inflammation, and predispose these mice to cardiac fibrosis. Therefore, a PAI-1 deficiency contributes to the development of cardiac fibrosis by increasing vascular permeability, exacerbating local inflammation, and increasing extracellular matrix remodeling, an environment conducive to accelerated fibrosis.
Figures







Comment in
-
PAI-1: cardiac friend or foe?Blood. 2010 Mar 11;115(10):1862-3. doi: 10.1182/blood-2010-01-261420. Blood. 2010. PMID: 20223930 No abstract available.
Similar articles
-
Plasminogen Activator Inhibitor Type I Controls Cardiomyocyte Transforming Growth Factor-β and Cardiac Fibrosis.Circulation. 2017 Aug 15;136(7):664-679. doi: 10.1161/CIRCULATIONAHA.117.028145. Epub 2017 Jun 6. Circulation. 2017. PMID: 28588076 Free PMC article.
-
Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.Sci Rep. 2017 Mar 23;7(1):365. doi: 10.1038/s41598-017-00418-y. Sci Rep. 2017. PMID: 28336948 Free PMC article.
-
Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition.Circulation. 2010 Sep 21;122(12):1200-9. doi: 10.1161/CIRCULATIONAHA.110.955245. Epub 2010 Sep 7. Circulation. 2010. PMID: 20823384
-
Plasminogen Activator Inhibitor Type-1 as a Regulator of Fibrosis.J Cell Biochem. 2018 Jan;119(1):17-27. doi: 10.1002/jcb.26146. Epub 2017 Jun 12. J Cell Biochem. 2018. PMID: 28520219 Review.
-
Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis.Kidney Int. 2000 Nov;58(5):1841-50. doi: 10.1111/j.1523-1755.2000.00355.x. Kidney Int. 2000. PMID: 11044203 Review.
Cited by
-
Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts.J Pharmacol Exp Ther. 2017 Apr;361(1):140-150. doi: 10.1124/jpet.116.237701. Epub 2017 Feb 7. J Pharmacol Exp Ther. 2017. PMID: 28174211 Free PMC article.
-
Transplantation of adipose tissue lacking PAI-1 improves glucose tolerance and attenuates cardiac metabolic abnormalities in high-fat diet-induced obesity.Adipocyte. 2020 Dec;9(1):170-178. doi: 10.1080/21623945.2020.1748961. Adipocyte. 2020. PMID: 32272863 Free PMC article.
-
Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.Exp Gerontol. 2015 Jan;61:62-75. doi: 10.1016/j.exger.2014.11.018. Epub 2014 Nov 28. Exp Gerontol. 2015. PMID: 25451236 Free PMC article.
-
Adipsin improves diabetic hindlimb ischemia through SERPINE1 dependent angiogenesis.Cardiovasc Diabetol. 2024 Dec 2;23(1):429. doi: 10.1186/s12933-024-02526-2. Cardiovasc Diabetol. 2024. PMID: 39623437 Free PMC article.
-
Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy.Basic Res Cardiol. 2021 Jan 11;116(1):1. doi: 10.1007/s00395-020-00840-w. Basic Res Cardiol. 2021. PMID: 33432417 Free PMC article.
References
-
- Maron BJ, Bonow RO, Cannon RO, III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987;316(13):780–789. - PubMed
-
- Kwak SH, Wang XQ, He Q, et al. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb Haemost. 2006;95(5):829–835. - PubMed
-
- Iwaki T, Sandoval-Cooper MJ, Brechmann M, Ploplis VA, Castellino FJ. A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice. Blood. 2006;107(10):3883–3891. - PubMed
-
- Ploplis VA, Tipton H, Menchen H, Castellino FJ. A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in ApcMin/+ mice. J Pathol. 2007;213(3):266–274. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous